Corgentech About
Corgentech: Corgentech Inc. (Nasdaq: CGTK) is a biopharmaceutical
company focused on the discovery, development and commercialization of a new class
of therapeutics called transcription factor decoys, or TF Decoys, which
work by blocking the activity of certain genes that are linked to disease. Because
abnormal gene expression is a fundamental cause of many diseases, controlling
the regulators of these genes—the transcription factors—offers an attractive therapeutic
approach. Corgentech is focused on TF Decoys initially for the treatment of cardiovascular
disease, inflammatory disease and cancer. Corgentech has a worldwide collaborative
agreement with Bristol-Myers Squibb Company (BMS) for the development and commercialization
of Corgentech's E2F Decoy. They also have additional TF Decoys in preclinical
development for the treatment of inflammatory diseases and cancer, and have retained
all rights to those TF Decoys.
Pipeline
Chart for Corgentech (all products) More
on Corgentech:
Key
Statistics for Corgentech
Phase
III E2F
Decoy Coronary
Bypass Graft Phase
I E2F
Decoy
Arterio-Venous Graft
Basic
Chart for Corgentech